Navigation Links
Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Date:8/19/2007

(10,284) (17,599) (20,516) (105,117)

Other income

(expenses):

Interest income 448 1,060 686 1,753 4,560

Interest expense (74) (86) (125) (179) (1,261)

Change in fair

value of warrant

Liability 471 (86) 127 (149) (454)

Other expense 2 - (1) - (1,181)

Loss before

tax benefit (8,624) (9,396) (16,912) (19,091) (103,453)

Income tax benefit - - - - 695

Net loss (8,624) (9,396) (16,912) (19,091) (102,758)

Deemed dividend (19,424) - (19,424) - (19,424)

Preferred stock

accretion (41) (310) (81) (351) (802)

Net loss

attributable

to common

stockholders $(28,089) $(9,706) $(36,417) $(19,442) $(122,984)

Net loss

attributable

to common

stockholders per

common share --

basic and diluted $(39.04) $(1.37) $(57.78) $(4.80)

Weighted-average

common shares

outstanding --

basic and

diluted 719,556 7,083,748 630,230 4,051,709

See accompanying notes to consolidated financial statements

Amicus Therapeutics, Inc

Statement of Operations Information for 3 months ending June 30, 2007

Change in

Fair

Value of Preferred Stock

Warrant Stock Compen- GAAP as

Non-GAAP Liability Accretion sation Reported

Income Statement

Classifications:

Research and development (6,361)
'/>"/>

SOURCE Amicus Therapeutics

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
3. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
8. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 310 Things to do This Summer 21 48398 110 Things to do This Summer 21 48398 210 Things to do This Summer 21 48398 3Naps with rapid eye movement sleep increase receptiveness to positive emotion 48396 1Naps with rapid eye movement sleep increase receptiveness to positive emotion 48396 2Caribbean coral reefs flattened 8781 1Caribbean coral reefs flattened 8781 2